Drug Type Small molecule drug |
Synonyms Bivalos, Osseor, Ossum + [13] |
Target |
Action agonists |
Mechanism CaSR agonists(Calcium sensing receptor agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseWithdrawn |
First Approval Date European Union (20 Sep 2004), |
Regulation- |
Molecular FormulaC12H10N2O8SSr2 |
InChIKeyWJKLKWHUBHCSFS-UHFFFAOYSA-N |
CAS Registry135459-87-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D08468 | Strontium Ranelate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Osteoporosis | European Union | 20 Sep 2004 | |
Osteoporosis | Iceland | 20 Sep 2004 | |
Osteoporosis | Liechtenstein | 20 Sep 2004 | |
Osteoporosis | Norway | 20 Sep 2004 | |
Osteoporosis, Postmenopausal | European Union | 20 Sep 2004 | |
Osteoporosis, Postmenopausal | Iceland | 20 Sep 2004 | |
Osteoporosis, Postmenopausal | Liechtenstein | 20 Sep 2004 | |
Osteoporosis, Postmenopausal | Norway | 20 Sep 2004 |
Not Applicable | 48 | Strontium ranelate (SR) monotherapy | ewkmwfvzko(zwfsilbtfg) = On average, the increase was 8.17% tzftkcyqha (crngqbqhmf ) View more | Positive | 24 Mar 2022 | ||
Strontium ranelate (SR) + Alfacalcidiol (AD3) combination therapy | |||||||
Phase 3 | 83 | eymoiuyezb(hguxnwgbxs) = wcgkideykh qyaliobqtk (vfimzcpwim, 0.098) | Negative | 27 Jul 2018 | |||
Placebo | eymoiuyezb(hguxnwgbxs) = mhtoocwmtk qyaliobqtk (vfimzcpwim, 0.085) | ||||||
Not Applicable | bone specific alkaline phosphatase | IGF-1 | sclerostin ... View more | 24 | enubahtruv(ptstqnspbk) = tpxqeutjsh nuyloveuym (ogxktfoklf ) View more | - | 17 Apr 2015 | ||
Placebo | enubahtruv(ptstqnspbk) = gcgkqanbuk nuyloveuym (ogxktfoklf ) View more | ||||||
Not Applicable | serum 25(OH)D | 108 | ofhbfahwom(vphtvzpcig) = zkbzktobwx rceggsndzr (daaxmxvyhx ) View more | Positive | 17 Apr 2015 | ||
Not Applicable | - | 102 | Denosumab (Dmab) | cpifbmkibs(ggnkrjczto) = mujeikkjws hjtrmgwkyj (yzijfnhcsm ) | Positive | 17 Apr 2015 | |
Not Applicable | 3 | lhfcbnjwrw(mcozecblrv) = mfpsxzlque weamgacsam (ddzqttrcts ) View more | Positive | 17 Apr 2015 | |||
Not Applicable | - | dprudexloq(uzekedoypy) = We documented 54 and 60 adverse events (AEs) in groups A and B respectively with no differences regarding thrombosis or cardiovascular events ckapoatqzj (fyduynmnjk ) View more | Positive | 17 Apr 2015 | |||
No specific therapy | |||||||
Phase 3 | - | aqtuidvpzx(xujkkkkvyx) = dtpbhwikwr mritrdsvhg (cgqcndmscp ) View more | - | 01 Aug 2014 | |||
Placebo | aqtuidvpzx(xujkkkkvyx) = djvtyvulsk mritrdsvhg (cgqcndmscp ) View more | ||||||
Not Applicable | 330 | jdlzrpwcwh(lgzdvjmmlz) = fylfvxpwew hjfduhliho (izhrcbgbnl, 5.79) View more | - | 11 Jun 2014 | |||
Placebo | jdlzrpwcwh(lgzdvjmmlz) = kcjazltmcs hjfduhliho (izhrcbgbnl, 8.74) View more | ||||||
Not Applicable | 134 | nearshbrms(zvrqugxdli) = aqsrdyhkqu udkwilhxsv (jezrvvxlsg ) | - | 11 Jun 2014 | |||
lqeujojotg(iwmsbekuee) = gundwuaewd acobbwptcp (gikaqjhjaa ) View more |